Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison.

about

Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.

P2860

Q54978927-C96F127A-5FE8-41F9-A514-E0FBDE4D421D

P2860

Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison.

Item

http://www.wikidata.org/entity/Q38648826

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Comparative Effectiveness of A ...... -Adjusted Indirect Comparison.

@en

type

Item

label

Comparative Effectiveness of A ...... -Adjusted Indirect Comparison.

@en

prefLabel

Comparative Effectiveness of A ...... -Adjusted Indirect Comparison.

@en

P1476

Comparative Effectiveness of A ...... -Adjusted Indirect Comparison.

@en

P2093

Avani Joshi

http://www.w3.org/2001/XMLSchema#string

Jinlin Song

http://www.w3.org/2001/XMLSchema#string

Keith A Betts

http://www.w3.org/2001/XMLSchema#string

Manish Mittal

http://www.w3.org/2001/XMLSchema#string

Martha Skup

http://www.w3.org/2001/XMLSchema#string

Vibeke Strand

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phas

Tumor necrosis factor inhibitors - state of knowledge.

Psoriatic arthritis: epidemiology, clinical features, course, and outcome.

Psoriatic arthritis therapy: NSAIDs and traditional DMARDs.

The Epidemiology of Psoriatic Arthritis.

Metabolic disorders in patients with psoriasis and psoriatic arthritis.

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).

Impact of psoriatic arthritis on the patient: through the lens of the WHO International Classification of Functioning, Health, and Disability.

Methods for Population-Adjusted Indirect Comparisons in Health Technology Appraisal.

P2888

s40744-017-0070-6

P304

349-362

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40744-017-0070-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1090933054

http://www.w3.org/2001/XMLSchema#string

P698

28762213

http://www.w3.org/2001/XMLSchema#string

P921

adalimumab

P932

5696282

http://www.w3.org/2001/XMLSchema#string

Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison.

about

P2860

P2860

Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921

P932